https://my.clevelandclinic.org/health/diagnostics/24204-breast-biopsy-overview

Key Words

Stereotactic core needle biopsy of the breast

Stereotactic core needle biopsy of the breast, as a highly technical and operationally dependent diagnostic method, the credibility of its results directly affects the treatment decisions and prognosis of patients. Therefore, establishing a rigorous quality control system and risk management strategy is the lifeline to ensure that this technology can fulfill its potential value. Any negligence in any aspect could lead to false negatives, insufficient samples, or diagnostic errors, resulting in disastrous consequences.

1. Quality Control Before Operation: Precise Positioning and Equipment Calibration

• Equipment calibration: The stereotactic system is a precise measuring instrument. Before each daily startup, it is necessary to calibrate using a standard phantom to verify whether the positioning accuracy along the X, Y, and Z axes meets the manufacturer's standards (typically with an error of <0.5mm). Any deviations must be corrected immediately.
• Image quality assurance: Ensure that the molybdenum target images are clear, with appropriate contrast, and without motion artifacts. The operating doctor should carefully review the images to confirm the true three-dimensional location of the lesion and plan the optimal puncture path, avoiding blood vessels, nerves, skin, and the chest wall.
• Informed consent and verification: Strictly implement the "Time Out" procedure. Before the operation, recheck the patient's identity, the side of the lesion (left/right), the consistency of the imaging data with the operation plan, and the consistency of the operation purpose, risks, and alternative solutions. Fully inform the patient of the operation purpose, risks, and alternative solutions, and sign the informed consent form.

2. Quality Control During Operations: Technical Specifications and Real-Time Feedback

• Needle puncture technique: Doctors must master the "coaxial technique," which involves first using a guiding needle to reach the predetermined depth, and then inserting the biopsy needle for sampling. This can reduce tissue damage and the risk of needle tract implantation. After each firing, it is necessary to immediately take "specimen X-ray" or "target point X-ray" through the stereotactic system to confirm whether the sampling slot accurately covers the lesion (especially for microcalcification). If the target is not found, the angle or depth should be adjusted for re-sampling.
• Sample processing: After removing the tissue strips, they should be carefully placed in a specially designed container containing formalin fixative to avoid squeezing or drying. For suspected calcified samples, it is best to mark them separately and take X-ray films to help the pathologist find the key area in the section.
• Complication monitoring: During the operation, closely observe the patient's reaction and ask if there is severe pain, dizziness, chest tightness, etc. After the operation, apply local pressure bandaging for at least 10-15 minutes to reduce the risk of hematoma formation. Inform the patient to avoid strenuous exercise and lifting heavy objects within 24 hours after the operation.

3. Quality Control After Operation: Pathological Alignment and Result Verification

• Pathology Request Form: It is essential to fill in detailed clinical information, including the patient's age, menstrual history, family history, imaging features (BI-RADS classification, lesion size, shape, presence or absence of calcification), puncture site, and number of needles. This is crucial for the pathologist to correctly interpret the results.
• Pathology Report Specifications: A qualified pathology report should include: gross description (number of tissue strips, color, texture), microscopic description (cell morphology, structure, presence or absence of necrosis, calcification), diagnostic conclusion (benign, atypical hyperplasia, carcinoma in situ, invasive cancer, etc.), and immunohistochemical results (ER, PR, HER2, Ki-67).
• Imaging-Pathology Correlation: This is the most important quality control step. Clinicians must compare the final pathological diagnosis with the preoperative imaging findings. If the pathological result is benign but does not match a highly suspicious imaging (such as BI-RADS 4C or 5 category), then the possibility of "sampling error" must be considered. It is necessary to recommend that the patient undergo a second biopsy, follow-up examination, or transfer to a surgical biopsy. Conversely, if the pathology is malignant but the imaging presentation is extremely atypical, it should also raise suspicion.

4. Risk Management and Continuous Improvement

• Reporting of adverse events: Establish a comprehensive system for reporting and analyzing complications (such as severe hematoma, infection, pneumothorax, needle tract implantation), and conduct regular reviews and summaries to identify systemic flaws.
• Training and assessment: All doctors and technicians involved in stereotactic core needle biopsy of the breast must undergo rigorous initial training and annual refresher training, and pass simulated operations and real-case assessments before they can operate independently.
• Data tracking: Regularly calculate key performance indicators such as the positive rate of biopsy, false negative rate, sample non-compliance rate, and complication rate of our unit, and compare them with industry benchmark data to continuously improve the operation process.

In conclusion, the reliability of stereotactic core needle biopsy of the breast is not inherent but is guaranteed by a comprehensive and meticulous quality control system. From the precise calibration of equipment to the proficient skills of doctors, from standardized sample processing to rigorous pathological-imaging comparisons, every step demonstrates respect for the patient's life and responsibility towards medical science. Only by adhering to high standards of quality management can this advanced technology truly become a reliable shield for safeguarding women's breast health.